These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23673288)

  • 1. Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Kitabatake S; Murakami Y
    Cytokine; 2013 Aug; 63(2):145-50. PubMed ID: 23673288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.
    Asahina Y; Tsuchiya K; Muraoka M; Tanaka K; Suzuki Y; Tamaki N; Hoshioka Y; Yasui Y; Katoh T; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nitta S; Sakamoto N; Izumi N
    Hepatology; 2012 Jan; 55(1):20-9. PubMed ID: 21898478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response.
    Asahina Y; Izumi N; Hirayama I; Tanaka T; Sato M; Yasui Y; Komatsu N; Umeda N; Hosokawa T; Ueda K; Tsuchiya K; Nakanishi H; Itakura J; Kurosaki M; Enomoto N; Tasaka M; Sakamoto N; Miyake S
    Gastroenterology; 2008 May; 134(5):1396-405. PubMed ID: 18471516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C.
    Ampuero J; Del Campo JA; Rojas L; García-Lozano JR; Solá R; Andrade R; Pons JA; Navarro JM; Calleja JL; Buti M; González-Escribano MF; Forns X; Diago M; García-Samaniego J; Romero-Gómez M
    Ann Hepatol; 2014; 13(4):356-63. PubMed ID: 24927606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
    Reddy KR; Govindarajan S; Marcellin P; Bernstein D; Dienstag JL; Bodenheimer H; Rakela J; Messinger D; Schmidt G; Ackrill A; Hadziyannis SJ
    J Viral Hepat; 2008 Feb; 15(2):129-36. PubMed ID: 18184196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
    Walsh MJ; Jonsson JR; Richardson MM; Lipka GM; Purdie DM; Clouston AD; Powell EE
    Gut; 2006 Apr; 55(4):529-35. PubMed ID: 16299039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C.
    AlQaraawi AM; Sanai FM; Al-Husseini H; Albenmousa A; AlSheikh A; Ahmed LR; Hersi A; Al-Otaibi MM; Syed M; Ali SM; Al-hamoudi W; Alswat KA; Abdo AA
    Dig Dis Sci; 2011 Apr; 56(4):1222-8. PubMed ID: 20931285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.
    Toyoda H; Kumada T; Hayashi K; Honda T; Katano Y; Goto H; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2011 Sep; 83(9):1559-64. PubMed ID: 21739446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of hepatitis B virus integration into liver tissue on the efficacy of peginterferon and ribavirin therapy in hepatitis B virus-negative chronic hepatitis C patients.
    Toyoda H; Kumada T; Tada T; Murakami Y
    J Clin Gastroenterol; 2014 Jan; 48(1):73-9. PubMed ID: 23842217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of
    Nakamoto S; Imazeki F; Kanda T; Wu S; Nakamura M; Yasui S; Tawada A; Mikata R; Chiba T; Arai M; Yokosuka O; Shirasawa H
    Int J Med Sci; 2017; 14(11):1088-1093. PubMed ID: 29104462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
    Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic Toll-Like Receptor 3 expression in chronic hepatitis C genotype 1 correlates with treatment response to peginterferon plus ribavirin.
    Yuki N; Matsumoto S; Kato M; Yamaguchi T
    J Viral Hepat; 2010 Feb; 17(2):130-8. PubMed ID: 19674283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
    Jian Wu Y; Shu Chen L; Gui Qiang W
    Liver Int; 2006 Mar; 26(2):166-72. PubMed ID: 16448454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.
    Khattab MA; Abdel-fattah ME; Eslam M; Abdelaleem A; Abdelaleem RA; Shatat M; Ali A; Hamdy L; Tawfek H
    J Clin Gastroenterol; 2010; 44(10):707-12. PubMed ID: 20195166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An early viral response to standard interferon-alpha identifies resistance to combination therapy with peginterferon and ribavirin in patients infected by HCV genotype 1.
    Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Takagi M; Hiramatsu T; Hosokawa T; Arakawa T; Fujimori M
    J Med Virol; 2010 Sep; 82(9):1537-44. PubMed ID: 20648607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype.
    Miyagi Y; Nomura H; Yamashita N; Tanimoto H; Ito K; Masaki N; Mizokami M; Shibuya T
    J Infect Chemother; 2013 Feb; 19(1):63-9. PubMed ID: 22821355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic interferon receptor mRNA expression: clinical relevance and its relationship with effectiveness of interferon plus ribavirin therapy in patients with genotype 1b hepatitis C virus infection.
    Lee CM; Kee KM; Hung CH; Eng HL; Chang CH; Huang CM; Wang JH; Hu TH; Lu SN; Changchien CS; Chen WJ
    Antivir Ther; 2006; 11(1):17-23. PubMed ID: 16518956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
    Westin J; Lagging M; Dhillon AP; Norkrans G; Romero AI; Pawlotsky JM; Zeuzem S; Schalm SW; Verheij-Hart E; Negro F; Missale G; Neumann AU; Hellstrand K;
    J Viral Hepat; 2007 Jan; 14(1):29-35. PubMed ID: 17212641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.
    Fukuhara T; Taketomi A; Motomura T; Okano S; Ninomiya A; Abe T; Uchiyama H; Soejima Y; Shirabe K; Matsuura Y; Maehara Y
    Gastroenterology; 2010 Nov; 139(5):1577-85, 1585.e1-3. PubMed ID: 20708617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.